Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform TrialSun Loo, Andrew H. Wei, Harry Iland et al.|Blood|2024Cited by 9
PB1796: ADMINISTRATION OF A KETOGENIC DIET FOR CHEMOTHERAPY PROTECTION IN ACUTE LEUKEMIA PATIENTS: IS IT FEASIBLE, SAFE, AND VALUABLE? PRELIMINARY RESULTS OF THE RANDOMIZED CONTROLLED TRIAL LEU-KETO STUDY.María Lastra Cagigas, Stephen J. Fuller, Abolfazl Ardjmand et al.|HemaSphere|2023Cited by 2